Dose Intensification of Busulfan in the Preparative Regimen is Associated with Improved Survival: A Phase I/II Controlled, Randomized Study  by Parmar, Simrit et al.
Biol Blood Marrow Transplant 19 (2013) 474e480American Society for Blood
ASBMT
and Marrow TransplantationDose Intensiﬁcation of Busulfan in the Preparative Regimen
is Associated with Improved Survival: A Phase I/II
Controlled, Randomized Study
Simrit Parmar 1,*, Gabriela Rondon 1, Marcos de Lima 1, Peter Thall 2,
Ronald Bassett 2, Paolo Anderlini 1, Partow Kebriaei 1, Issa Khouri 1,
Prasanth Ganesan 1, Richard Champlin 1, Sergio Giralt 3
1Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas at MD Anderson Cancer Center, Houston,
Texas
2Department of Biostatistics, The University of Texas at MD Anderson Cancer Center, Houston, Texas
3Memorial Sloan Kettering Cancer Center, New York, New YorkArticle history:
Received 15 November 2012
Accepted 3 December 2012
Key Words:
Reduced-intensity transplant
Intravenous busulfan
Relapsed/refractory leukemiaFinancial disclosure: See Acknowl
* Correspondence and reprint r
Professor, MD Anderson Cancer C
TX 77030.
E-mail address: sparmar@mdan
1083-8791/$ e see front matter 
http://dx.doi.org/10.1016/j.bbmt.20a b s t r a c t
Dose intensity is important for disease control in patients undergoing allogeneic stem cell transplantation.
We conducted a phase I/II controlled, adoptive, randomized study to determine the optimal dosing schedule
of i.v. busulfan. Patients aged 75 years with advanced hematologic malignancies with human leukocyte
antigenecompatible donor were eligible. All patients received ﬂudarabine at 30 mg/m2/d for 4 days, and
busulfan was administered in different doses in oral or i.v. formulations. As determined by the phase I trial, i.v.
busulfan at a dose of 11.2 mg/kg/d was used for the phase II expansion cohort. Altogether, 80 patients with
a median age of 56 years were enrolled. Forty percent had active disease at the time of transplantation.
Engraftment occurred in 91%, and a complete response was achieved in 79% of patients posttransplantation.
At a median follow-up of 91 months in the surviving patients, the outcomes for i.v. busulfan dose of 11.2 mg/
kg/d versus other doses were as follows: nonrelapse mortality, 34% versus 23% (P ¼ .4); cumulative incidence
of relapse, 43% versus 68% (P ¼ .02); relapse-free survival, 25% versus 9% (P ¼ .017); and overall survival, 27%
versus 9% (P ¼ .02). We conclude that optimizing i.v. busulfan dose intensity in the preparative regimen may
overcome disease-associated poor prognostic factors.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION active disease at the time of transplantation is still associated
Reduced-intensity conditioning (RIC) is associated with
low nonrelapse mortality (NRM) and has made it possible to
offer allogeneic stem cell transplantation (allo-SCT) to the
older population. Several large registry studies have shown
that the lower NRM seen in RIC comes at the cost of increased
relapsed rates [1-3].
Myeloablative doses of i.v. busulfan in combination with
either ﬂudarabine or cyclophosphamide have been associ-
ated with favorable outcomes, but signiﬁcant toxicities and
treatment-related morbidity and mortality remain a major
concern [4-6]. Slavin et al. ﬁrst reported the successful
combination of oral busulfan with ﬂudarabine, which resul-
ted in 100% engraftment and was associated with long-term
disease control in 77.5% [7]. Since then, i.v. busulfan has
largely replaced its oral formulation as part of the prepara-
tive regimen due to more predictable pharmacokinetics and
ability to perform dose adjustments to avoid excess toxicities
[4,6,8]. Bypassing the oral route to achieve 100% bioavail-
ability has translated into improved control over drug
administration, with increased safety and reliability to
maximize the antileukemic efﬁcacy.
A recent report revealed a promising association with use
of the i.v. form of busulfan and a lower NRM, even in sicker or
older populations [9]. However, high-risk disease and/oredgments on page 480.
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12.12.001with poor outcomes [10-14]. Levine et al. demonstrated poor
outcome associated with lower doses of busulfan in the
conditioning regimen, especially in patients with advanced
disease [12]. In a retrospective analysis of 31 patients, 8 mg/
kg busulfan was associated with better disease control when
compared with a less intense regimen of 4 mg/kg [15].
However, other studies have not found an advantage with
higher-dose busulfan regimens. Hamadani et al. reported (in
a retrospective analysis) no difference in the outcomes
between RIC busulfan-ﬂudarabine (6.4 mg/kg total dose of
busulfan) compared with a more intense regimen (130 mg/
m2 of busulfan for 4 days, roughly equivalent to 12.8 mg/kg
cumulative dose) [16]. However, there were major differ-
ences in the patient proﬁles of two study arms, with more
acute leukemias in the intense therapy arm and more indo-
lent diseases like chronic lymphocytic leukemia in the less
intense arm. Therefore, optimization of busulfan-containing
conditioning regimens is needed to improve clinically rele-
vant patient outcomes.
We conducted a prospective phase I/II Bayesian adop-
tively randomized study to determine the best dose, dosing
schedule, and efﬁcacy of i.v. busulfan in combination with
ﬂudarabine as a preparative regimen for allo-SCT.
METHODS
Patients
Patients younger than age 75 years undergoing allo-SCT from human
leukocyte antigen (HLA)-A, -B, and -DR matched unrelated donors or 5/6
matched related donors with the following diagnoses were eligible: chronic
myeloid leukemia, which was either transformed or interferon-resistant;
acute myeloid leukemia; intermediate or high-risk myelodysplastic
syndrome, as deﬁned by the International Prognostic Scoring System; andTransplantation.
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considered unqualiﬁed to undergo an ablative preparative regimen because
of advanced age or the presence of comorbidities.
Patients had to be in ECOG performance status 2 with adequate
hepatic (bilirubin < 3 mg/dL) and renal (creatinine < 2.5 mg/dL) function.
The goal was to identify the optimal dose and schedule of i.v. busulfan in
combination with a ﬁxed dose of ﬂudarabine as an RIC regimen.
The study was reviewed and approved by the Institutional Review Board
of the University of Texas-MD Anderson Cancer Center. Informed consent
was obtained from the patients and donors. Unrelated donors gave consent
according to the National Marrow Donor Registry policies. Assessment of
graft-versus-host disease (GVHD) was performed according to the
consensus criteria [17]. Toxicities were assessed according to the National
Cancer Institute common toxicity criteria (NCI CTC version 3, http://ctep.
cancer.gov/reporting/ctc.html).
Treatment Plan
Fludarabine was administered at a dose of 30 mg/m2/d before
busulfan on days -5, -4, -3, and -2 to all patients. Equine antithymocyte
globulin (10 mg/kg/d 4 times on days -4, -3, -2, and -1) was added for
patients receiving mismatched related or matched unrelated donor (MUD)
transplantations. In the phase I portion of the study, 7 dose levels of
busulfan were explored, with each level delivered either once a day or every
6 hours (Table 1). Drugs were dosed according to adjusted body weight in
patients whose actual weight was at least 120% of the ideal body weight.
Actual weightwas used for the rest of the patients. At the time of performing
this trial, the resources for performing busulfan pharmacokinetics were
not available.
Supportive Care
Patients received GVHD prophylaxis using tacrolimus targeting a blood
level of 5 to 15 ng/mL and methotrexate (5 mg/m2 on days 1, 3, 6, and 11).
Patients were allowed to be on any active GVHD prophylaxis protocols.
Infectious disease prophylaxis generally included ﬂuconazole, acyclovir, and
ciproﬂoxacin. Ganciclovir was used on a preemptive basis for patients with
cytomegalovirus antigenemia or viremia, which was monitored on a weekly
basis. Patients received granulocyte colony-stimulating factor 5 mg/kg
subcutaneously daily from day þ7 onward until they achieved an absolute
neutrophil count >1.5  109/L for 3 days. Filtered and irradiated blood
product transfusions were given to maintain hemoglobin >8 g/dL and
platelets >20,000/cm3.
Statistical Design and Analysis
This was a phase I/II Bayesian, adoptively randomized, dose-ﬁnding
study that took into account both toxicity and efﬁcacy. Patients were eval-
uated based on age, organ function, and donor match.
Study endpoints
The major endpoints assessed during the study were engraftment
(deﬁned as absolute neutrophil count >0.5  109/L for 3 days), platelet
recovery (platelet recovery >20  109/L, independent of platelet
transfusions), infectious complications, achievement of complete
remission (<5% blasts in the bone marrow with trilineage differentiation
and freedom from platelet transfusion and absolute neutrophil
count >0.5  109/L), development and grade of acute GVHD, chimerism
over time, and toxicity. Overall survival (OS) was calculated as the time
from the date of transplantation to the date of death or censored at the
date of last follow-up. NRM at 100 days (NRM100) was deﬁned as the
binary indicator of death within the ﬁrst 100 days without relapse.
Relapse-free survival (RFS) was calculated as the time from the trans-
plantation date to the date of disease relapse or death, whichever wasTable 1
Intravenous Busulfan Dosing Schedule
Day Flu
(mg/m2)
Dose Level 0 Dose Level 1 Dose Level 2 Dose
BU q.i.d.
(mg/kg)
BU Daily
(mg/kg)
BU q.i.d.
(mg/kg)
BU Daily
(mg/kg)
BU q.i.d.
(mg/kg)
BU Daily
(mg/kg)
BU q
(mg/
-5 30 .8  4 3.2 .8  4 3.2 .8  4 3.2 .8 
-4 30 .8  2 1.6 .8  4 3.2 .8 
-3 30 .8 
-2 30
-1 Rest
0 SCT infusion
Seven dose levels of i.v. busulfan were administered either as a daily dose or divided
transplantation recipients received antithymocyte globulin.
Flu indicates ﬂudarabine; BU, busulfan.earlier. Patients who were alive without relapse at the end of the study
were censored at the date of last follow-up. The four covariates of interest
were age, cytogenetic risk category (good, intermediate, or bad), dose of
busulfan received, and the percent of bone marrow blasts.
Dose-ﬁnding strategy
Based on factors inﬂuencing toxicity occurring from the preparative
regimen, including patient age, organ function, and degree of donor match,
patients were separated into 2 strata in consideration for the toxicity for
phase I endpoints: “good” risk, as deﬁned by good organ function, age <60
years for patients with sibling-matched donors and age <50 years for MUD
and “poor” risk, as deﬁned by all other patients who met the eligibility
criteria. As described earlier, 2 deliverymodes, daily dose and dosing every 6
hours, were examined. Within each mode, a maximum tolerated dose was
determined among different intravenous busulfan dose levels using the
continual reassessment method [18,19] with a probability of 20% for grade 3
to 4 organ toxicity.
Phase II portion of the study
Phase II was conducted using the maximum tolerated dose selected in
phase I with the goal of keeping the failure rate below the historical rate of
.05 and reduce the death rate by .20 using the monitoring method described
by Thall et al. [20].
Statistical Methods
The continual reassessment method [18,19] was used for dose ﬁnding in
phase I. The method of Thall et al. [20] was used for safety monitoring in
phase II. Bayesian regression models [21] were ﬁt to assess the effects of the
covariates of interest on the following outcomemeasurements: OS, RFS, and
NRM100. For the time-to-event outcomes (OS and RFS), goodness-of-ﬁt
tests were performed using the Bayesian Information Criterion [22] to
choose the best-ﬁtting model from among the Weibull, normal, log normal,
logistic, log logistic, exponential, and gamma distributions. For the dichot-
omous outcome NRM100, Bayesian logistic regression models were ﬁt. For
each model ﬁt, we assumed that each parameter in the linear term followed
a noninformative normal prior with mean 0 and variance 10. All calculations
were performed in R version 2.12.0 and OpenBUGS version 3.1.2 rev 668
[23]. The cumulative incidence of relapse and NRM were analyzed in
a competing risks framework [24], and distributions were compared using
the methods of Fine and Gray [25].
RESULTS
Eighty patients with a median age of 56 years (range, 10
to 71 years) and active disease in 32 patients (40%) were
enrolled in the study from March 2000 to October 2004
(Figure 1). Median follow-up for survivors was 91 months
(range, 25.5 to 125.7 months). Patient characteristics are
described in Table 2. Forty patients had a matched related
donor, and 35 patients had a mismatched related or unre-
lated donor as a source of stem cells for the allo-SCT. Five
patients (mismatch related donor, 1; MUD, 4) received ﬂu-
darabine, busulfan, and alemtuzumab (12%). Forty-two
patients received peripheral blood progenitor cells, and 38
underwent bone marrow transplantations. The median
number of infused CD34 þ cells was 4.7  106/kg, and the
median total nucleated count infused was 4.1  108 cells/kg.
GVHD prophylaxis was tacrolimus and methotrexate inLevel 3 Dose Level 4 Dose Level 5 Dose Level 6
.i.d.
kg)
BU Daily
(mg/kg)
BU q.i.d.
(mg/kg)
BU Daily
(mg/kg)
BU q.i.d.
(mg/kg)
BU Daily
(mg/kg)
BU q.i.d.
(mg/kg)
BU Daily
(mg/kg)
4 3.2 .8  4 3.2 .8  4 3.2 .8  4 3.2
4 3.2 .8  4 3.2 .8  4 3.2 .8  4 3.2
2 1.6 .8  4 3.2 .8  4 3.2 .8  4 3.2
.8  2 1.6 .8  4 3.2
into 4 doses (q.i.d.). All patients received i.v. ﬂudarabine. All unrelated donor
Figure 1. Enrollment diagram.
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1 patient received additional extracorporeal photopheresis,
and 7 received additional pentostatin [26].Table 2
Patient Characteristics
Dose Level
0 (n ¼ 2)
Dose Level
2 (n ¼ 4)
D
3
Busulfan dose freqency
Daily dose 2 2 2
q.i.d. dose 0 2 2
Age  60 yr 1 3 2
Median age at SCT, yr 54 63 61
Gender, male 0 4 4
Diagnosis
AML/MDS 1 3 3
CML 1 1 1
Other* 0 0 0
Abnormal cytogenetics 1 2 4
Disease status at SCT
CR 0 3 2
Refractory/progressive 2 1 2
BM blasts > 5% 1 2 4
Type of transplantation
MUD 0 2 3
MRDy 2 2 1
Stem cell source
BM 0 3 4
PB 2 1 0
TNC (e8/kg)  108 4.9 2.7 2
CD34 (e6/kg)  106 5.4 6.2 4
CD3 (e6/kg)  106 166.7 29.7 24
AML indicates acutemyelogenous leukemia;MDS, myelodysplastic syndrome; CML
MRD, matched related donor; PB, peripheral blood; TNC, total nucleated count.
* Lymphoma, 3; acute lymphoblastic leukemia, 1.
y Seven of 47 had 1 antigen mismatch.Six cohorts of 2 patients each were treated with each of
the 2modalities with a schedule of either once a day or every
6 hours, for a total of 12 patients per modality and 24ose Level
(n ¼ 4)
Dose Level
4 (n ¼ 7)
Dose Level
5 (n ¼ 58)
Dose Level
6 (n ¼ 5)
4 54 3
3 4 2
1 23 0
44 57 39
5 37 4
6 46 4
1 8 1
0 4 0
5 36 2
3 34 3
4 24 2
5 27 4
2 25 2
5 33 3
2 26 3
5 32 2
.7 3.8 4.6 2.7
.3 4.3 4.7 5.5
.5 87.8 74.2 28
, chronicmyelogenous leukemia; CR, complete remission; BM, bonemarrow;
Table 3
Patient Characteristics: Dose Level 5 versus Others
Dose Level
5 (n ¼ 58)
Others
(n ¼ 22)
P Value
Busulfan dose frequency .001
Daily dose 54 (93%) 13 (59%)
q.i.d. dose 4 (7%) 9 (41%)
Age  60 yr 23 (40%) 7 (32%) .6
Median age at SCT, yr 57 54 NS
Gender, male 37 (64%) 17 (77%)
Diagnosis
AML/MDS 43 (74%) 17 (77%)
CML 11 (19%) 5 (23%)
Other* 4 (7%) 0
Abnormal cytogenetics 36 (62%) 14 (64%) .7
Relapsed/refractory disease
at time of SCT
23 (38%) 9 (41%) .15
Type of transplantation 1.0
MUD 25 (43%) 9 (41%)
MRDy 33 (57%) 13 (59%)
Stem cell source .463
BM 26 (45%) 12 (55%)
PB 32 (55%) 10 (45%)
TNC (e8/kg) 4.6 3.4
CD34 (e6/kg) 4.75 5
CD3 (e6/kg) 74.3 32
AML indicates acute myelogenous leukemia; MDS, myelodysplastic
syndrome; CML, chronic myelogenous leukemia; BM, bone marrow; MRD,
matched related donor; PB, peripheral blood; TNC, total nucleated count.
* Lymphoma, 3; acute lymphoblastic leukemia, 1.
y Seven of 47 had 1 antigen mismatch.
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levels of i.v. busulfan were examined: 9.6 mg/kg, 11.2 mg/kg,
and 12.8 mg/kg. The starting dose was chosen based on our
experience and the published literature at the time of the
study [7]. For the poor-risk cohort (n ¼ 49), 4 dose levels of
i.v. busulfanwereexamined:8.0mg/kg, 9.6mg/kg,11.2mg/kg,
and 12.8 mg/kg.
Patient characteristics and their distribution are shown in
Table 2. The maximum tolerated dose established from the
phase I study for both good and high-risk cohorts was i.v.
busulfan at 11.2 mg/kg. After completion of enrollment of 32
patients in the phase I portion, the subsequent 48 patients
were enrolled into the phase II part of the study on i.v.
busulfan dose level 11.2 mg/kg (dose level 5). Because most
patients (73%) in the trial received this dose level 5, it was
recoded as a dichotomous variable: dose level 5 versus all
other doses combined (Table 3) for outcome analysis. All
patients were included in the ﬁnal planned analysis.Table 4
Transplantation Outcomes in the Entire Cohort
Dose Level
0 (n ¼ 2)
Dose Level
2 (n ¼ 4)
Graft failure 1 1
Time to neutrophil engraftment, d 13 17
Time to platelet engraftment, d 8 18
Grades II-IV aGVHD 0 2
Grades III-IV aGVHD 0 1
Time to aGVHD, d d 34.5
Chronic GVHD 0 0
Time to chronic GVHD, mo d d
Progression, n 1 3
Median time to progression, d 70 26
Dead, n 2 4
Dead at 100 days without relapse 1 1
Dead at 1 yr without relapse 1 1
Median time to death, d 167 48Toxicity
The most common (20%) adverse events of any grade,
regardless of the relationship to the preparative regimen,
were increased creatinine (33.7%), diarrhea (35%), infection
(32.5%), mucositis (51%), nausea (57.5%), skin rash (37.5%),
and transaminitis (35%). Regimen-related grade 3 or higher
toxicity included bleeding (2.5%), diarrhea (2.5%), increased
bilirubin (2.5%), hematuria (1.2%), high blood pressure
(1.2%), mucositis (1.2%), neutropenia (1.2%), and skin
rash (1.2%).
One patient developed veno-occlusive disease at 67 days
posttransplantation that was associated with altered mental
status, hepatic encephalopathy, and raised transaminitis.
Liver biopsy showed a mild increase in periportal ﬁbrosis
with no evidence of cirrhosis and severely increased iron
deposition. The patient was subsequently found to have
severe iron overload and improved with phlebotomy. Ulti-
mately, the patient died from steroid-refractory GVHD.
Overall, 57% of patients had documented infections. Iso-
lated organisms included alpha-hemolytic streptococci
(n ¼ 1), BK virus (n ¼ 2), C. difﬁcile (n ¼ 1), cytomegalovirus
reactivation (n ¼ 6), coagulase-negative staphylococcus
(n¼ 4), E. coli (n¼ 1), klebsiella (n¼ 1), parainﬂuenza (n¼ 1),
Pseudomonas aeruginosa (n ¼ 7), rhizopus (n ¼ 1), and
vancomycin-resistant enterococcus (n ¼ 3). One patient had
West Nile virus encephalitis.
Engraftment, Chimerism, and GVHD
Engraftment occurred in 73 patients (91%). No differences
were seen in the engraftment rate between i.v. busulfan dose
level 11.2mg/kg and other groups (91.4% vs 91%, respectively;
P ¼ NS). There were 3 early deaths and 4 graft failures.
Signiﬁcant correlation was found between graft failure and
persistent disease in the posttransplantation setting (chi-
square; P< .0001). Among thosewho engrafted, 37 (50%) had
full-donor chimerism. Routinely performed chimerism
studies revealed the development of mixed chimerism
(<99% donor cells detected in peripheral blood on more than
one occasion) in 32 patients. Among these patients, >90%
donor chimerism was seen in 12 patients (38%). The median
degree of chimerism in these patients was 86.5% (range, 12%
to 98%), and a signiﬁcant correlation was demonstrated
between the incidence of mixed chimerism and persistent
disease in the posttransplantation setting (chi-square;
P < .0001). The median time to neutrophil engraftment was
13 days and to platelet engraftment was 17 days. The
engraftment data for the whole cohort are shown in Table 4.Dose Level
3 (n ¼ 4)
Dose Level
4 (n ¼ 7)
Dose Level
5 (n ¼ 58)
Dose Level
6 (n ¼ 5)
0 0 2 0
16 12 13 13
20 22 15 18
3 2 17 2
0 0 5 2
48 26 46 35.5
0 2 19 1
d 4.3 7.1 4.3
2 5 26 4
25.5 54 64.5 81
2 6 43 5
0 0 6 0
0 2 14 0
65 165 157 258
Table 5
Transplantation Outcomes for Dose Level 5 versus Others
Dose Level
5 (n ¼ 58)
Other Dose
Levels (n ¼ 22)
P Value
Graft failure 2 2 NS
Time to neutrophil engraftment,
days
13 13 NS
Time to platelet engraftment,
days
15 18 NS
Grades II-IV aGVHD 17 (29.3%) 9 (42%) NS
Chronic GVHD 19 (32.8%) 4 (13.6%) .087
Progression, n 25 (43%) 15 (68%) .045
Dead, n 43 (74%) 20 (91%) .1
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terms of graft failure, time to neutrophil engraftment days, or
time to platelet engraftment (Table 5).
Among the engrafted patients, grades II-IV acute GVHD
(aGVHD) occurred in 26 patients (35.6%), and grades III-IV
aGVHD occurred in 8 patients (11%). The median time to
onset of aGVHD was 43.5 days (range, 13 to 208 days).
Distribution of aGVHD was primarily to the skin (n ¼ 34)
followed by the gastrointestinal tract (n ¼ 10) and liver
(n ¼ 2). The aGVHD distribution for the whole cohort is
shown in Table 4. There were no differences in the aGVHD
rates between dose level 5 versus others (Table 5). Chronic
GVHD occurred in 22 patients (27.5%) involving skin (n¼ 11),
gastrointestinal tract (n ¼ 7), liver (n ¼ 3), and eyes (n ¼ 2).
Again, no signiﬁcant differences were seen between dose
level 5 patients versus others.Nonrelapse Mortality
Table 6 demonstrates the results of multivariate analysis
of NRM100. Advanced age at the time of transplantation was
the only signiﬁcant factor predicting worse outcome.
NRM100 was 10% for the whole cohort (due to infections, 3;
aGVHD, 2; graft failures, 2; alveolar hemorrhage, 1). The 1-
year NRM was 23.8% (due to GVHD, 10; infection, 4; graft
failure, 2; hemorrhage, 2; unknown, 1). At the 8-year follow-
up, no signiﬁcant difference was seen for NRM, 34% for i.v.
busulfan dose level 11.2 mg/kg, and 23% was seen in all
others (P ¼ .4, Figure 2A).Relapse and Survival
The 8-year cumulative incidence of relapse of 43% was
signiﬁcantly less in the patients receiving busulfan at 11.2Table 6
Summary of Bayesian Logistic Regression Model for Transplantation-Related Mort
Variable NRM100 RFS
Mean SD 95% CI Pr
(Harmful
Effect)
Mean SD
Intercept 3.042 .918 1.033 .3
Age .126 .062 .021, .265 .992 .012 .0
Cytogenetics bad
(vs intermediate)
.739 .872 1.055, 2.388 .812 .924 .4
Cytogenetics good
(vs intermediate)
1.845 2.292 6.560, 2.022 .221 1.234 .7
Cytogenetics unknown
(vs intermediate)
.471 1.398 2.541, 2.916 .662 .330 .6
Log (no. of blasts) .138 .215 .550, .283 .252 .173 .0
Dose level 5
(vs all other levels)
.361 .907 2.127, 1.471 .337 .801 .4
Pr indicates Probability; CI, conﬁdence interval; SD, standard deviation.mg/kg as compared with 68% relapse seen in other dose
levels (P ¼ .02, Figure 2B). In multivariate analysis, RFS was
superior for patients receiving i.v. busulfan at 11.2 mg/kg
(Table 6). The 5-year RFS was 25% for dose level 5 patients
versus 9% for all others (P ¼ .017; Figure 2B). Disease-related
poor prognostic factors, including bad cytogenetics and
increased bone marrow blasts, were also associated with
worse RFS.
At a median follow-up of 91 months in the surviving
patients, the 5-year OS rate for patients treated with i.v.
busulfan 11.2 mg/kg was 27% compared with 9% for patients
treated at the other dose levels (P ¼ .02; Figure 3B). In
multivariate analysis, improved OS was seen in dose level 5
patients (Table 6). Older age, unfavorable cytogenetics, and
increased bone marrow blasts were also associated with
worse OS (Table 6).
Because indication for allo-SCT was acute myeloid
leukemia and/or myelodysplastic syndrome in 75% of the
patients in our study, we speciﬁcally studied outcomes in
this population. The 5-year OS rate for the whole cohort was
18%. Signiﬁcant improvement in OS was seen in patients
receiving i.v. busulfan at the 11.2mg/kg dosewhen compared
with others: 23% versus 5% (P ¼ .019). The causes of deaths
for the whole cohort were progressive disease in 39 (48.8%),
GVHD in 12 (15%), infection in 5 (6.3%), graft rejection in 2
(2.5%), hemorrhage in 2 (2.5%), myocardial infarction in 1,
and unknown in 2.Potential Candidates for High-Dose Busulfan: Impact of
Transplantation Risk Factors
Among the patients receiving i.v. busulfan at 11.2 mg/kg,
we sought to examine whether the transplantation prog-
nostic risk factors would affect the overall outcomes. In this
category, signiﬁcantly improved median overall survival of
12.3 months was observed in patients with good prognostic
risk factors versus 6.3 months seen in patients with poor risk
factors (P¼ .04; log rank). Similarly, a trend toward improved
RFS of 9.4 months was seen in the patients with good
prognostic risk factors compared with 4.6 months in patients
with poor prognostic risk factors (P ¼ .08, log rank).Four Times a Day versus Daily Dosing
No signiﬁcant differences were seen in terms of mortality,
OS, or progression-free survival when comparing doses of
once daily or four times a day of busulfan.ality by Day 100 and RFS and OS Rates
OS
95% CI Pr
(Beneﬁcial
Effect)
Mean SD 95% CI Pr
(Beneﬁcial
Effect)
59 .637 .327
15 .042, .017 .198 .025 .014 .052, .017 .035
01 1.722, .143 .011 .667 .370 1.380, .063 .035
26 .214, 2.678 .954 1.105 .662 .185, 2.406 .953
45 1.585, .917 .307 .326 .592 1.474, .825 .293
91 .348, .005 .027 .113 .084 .274, .057 .092
12 .014, 1.608 .973 .761 .378 .015, 1.487 .977
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Figure 2. (A) Cumulative incidence of NRM with competing risk of relapse. (B)
Cumulative incidence of relapse.
Figure 3. (A) Overall survival. (B) Relapse-free survival.
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We report the results of a phase I/II study of i.v. busulfan
containing reduced-intensity preparative regimen, without
pharmacokinetic monitoring, for older or medically inﬁrm
patients with advanced hematologic malignancies, not
otherwise considered eligible for myeloablative condi-
tioning. This trial further validated a set of favorable trans-
plantation risk factors (independent of the disease status)
that included good organ function, age <60 years for sibling
matched donor transplantation, and age <50 years for MUD
transplantations that were associated with improved
outcomes with a 5-year OS of 40% and RFS of 36%.
A large proportion of our study populationwas older than
60 years of age (38%) and harbored high risk. As shown
previously, a similar patient population with active disease
at the time of transplantation are unlikely to achieve durable
remissions and are associated with poor outcomes [27,28].
However, in our study, remissionwas achieved in 63 patients
(79%) after the transplantation in the whole cohort and in
84% for those receiving busulfan at 11.2 mg/kg. Speciﬁcally,
improved survival was associated with i.v. busulfan 11.2 mg/
kg dose among patients diagnosed with acute myeloid
leukemia and/or myelodysplastic syndrome, which is a hard-
to-treat population. Furthermore, improved relapse rates of
43% were associated with the i.v. busulfan dose intensiﬁca-
tion but not at the cost of toxicity. In fact, NRM rates
exceeding 40% have been reported in a younger population
as compared with our patients, with relatively less advanced
disease but a comorbidity index 3 [29], whereas in ourstudy, the NRM was 31% for the whole cohort. Although
most of the patients were heavily pretreated, we did not
see any increase in liver toxicity, and, speciﬁcally, only
one patient developed veno-occlusive disease. As expected,
increased bone marrow blasts and poor cytogenetics
still remained as poor predictors of outcome, and novel
posttransplantation therapies, including demethylating
agents, continue to be explored as a posttransplantation
strategy [30,31].
In our study, 44% of engrafted patients demonstrated
mixed chimerism. This is not surprising because mixed
chimerism rates of up to 65% have been shown in the setting
of RIC using a busulfan-ﬂudarabine combination [32]. In
addition, we used strict criteria of <99% donor chimerism to
deﬁne mixed chimerism. Furthermore, the incidence of
mixed chimerism correlated with persistent disease in the
posttransplantation setting (chi-square; P < .0001).
In conclusion, optimizing the busulfan dose in the
preparative RIC regimen led to improvement of the anti-
tumor activity of conditioning without signiﬁcant regimen
toxicity, which led to decreased relapse and improved
survival. Speciﬁcally, we did not experience increased
toxicity with higher busulfan doses up to 11.2 mg/kg, even in
the absence of the guidance provided by the pharmacoki-
netic monitoring of busulfan. Therefore, in areas where
busulfan monitoring is difﬁcult, adopting the dose level of
11.2 mg/kg may seem to be a reasonable option for elderly
and medically inﬁrm patients with high-risk disease.
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